logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Tag: Agenus (AGEN)

The Time Has Come for Agenus to Excel. See Also: Why Evoke Pharma Traded UP Today

Agenus Has Two Separate Press Releases In the First Press Release from Agenus: Agenus ( AGEN ) announced that it will be making a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181 at the American Association...

Read More

June 22, 2020

0

Agenus Strategic Decision to Withdraw the BLA for Balsitilimab

Agenus to Withdraw BLA for Balstilimab Agenus ( AGEN ) announced a strategic decision to withdraw its Biologics License Application ( BLA ) for balstilimab, its PD-1 inhibitor. The firm stated that its decision will not change the development plans...

Read More

October 22, 2021

0

Agenus Inc Corporate Update and Financial Results for Q2 2021. See Also: Why Intellia Was Down Today

Agenus Inc News and Q2 Results for 201 Agenus ( AGEN ) announced results with better than usual news including the following:  $200 million received from BMS for anti-TIGIT bispecific antibody collaboration FDA cleared IND for AGEN1777 clinical enrollment AGEN1181...

Read More

August 9, 2021

0

Agenus: Could It Be a Resurrection? See Also: Prohost Performing Stocks

Agenus Announced Data from Phase 2 Trials of Balstilimab Agenus ( AGEN ) immuno-oncology company announced that data from two Phase 2 trials of balstilimab alone and in combination with zalifrelimab will be orally presented in at the upcoming European Society...

Read More

September 2, 2020

0

Agenus Stock Rallied Yesterday

Why Agenus Stock Rallied Yesterday On September 2, 2020 we posted an article about Agenus ( AGEN ) under Trick or Trade titled, “ Agenus: Could It Be a Resurrection? "   The article was about the data Agenus announced from...

Read More

September 11, 2020

0

Agenus Good News: Balstilimab Monotherapy Data Published in Gynecologic Oncology

Agenus Good News for Balstilimab Monotherapy Agenus ( AGEN ) announced that results from a global Phase 2 clinical study of balstilimab monotherapy in recurrent/metastatic cervical cancer were published online in the international peer-reviewed journal  Gynecologic Oncology . From the...

Read More

August 27, 2021

0

Agenus Strategic Decision to Withdraw the BLA for Balsitilimab

Agenus to Withdraw BLA for Balstilimab Agenus ( AGEN ) announced a strategic decision to withdraw its Biologics License Application ( BLA ) for balstilimab, its PD-1 inhibitor. The firm stated that its decision will not change the development plans...

Read More

October 22, 2021

0

An Important Agreement Between Bristol-Myers Squibb and Agenus

Bristol-Myers Squibb and Agenus Agreement for AGEN1777 Bristol-Myers Squibb ( BMY ) and Agenus ( AGEN ) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to...

Read More

May 18, 2021

0

Agenus Inc Corporate Update and Financial Results for Q2 2021. See Also: Why Intellia Was Down Today

Agenus Inc News and Q2 Results for 201 Agenus ( AGEN ) announced results with better than usual news including the following:  $200 million received from BMS for anti-TIGIT bispecific antibody collaboration FDA cleared IND for AGEN1777 clinical enrollment AGEN1181...

Read More

August 9, 2021

0

Agenus Good News: Balstilimab Monotherapy Data Published in Gynecologic Oncology

Agenus Good News for Balstilimab Monotherapy Agenus ( AGEN ) announced that results from a global Phase 2 clinical study of balstilimab monotherapy in recurrent/metastatic cervical cancer were published online in the international peer-reviewed journal  Gynecologic Oncology . From the...

Read More

August 27, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 13
  • 14
  • 15
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy